STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Molecular Biotechnological Research Original Research

Multitarget Molecular Docking Using Curcuma longa Phytocompounds for Polycystic Ovary Syndrome Treatment

  1. Basamma D.B. Department of Moleculr Pathology Laboratory, Triesta Science, A Unit of HCG Hospital, Bangalore

Abstract

Objective: The primary goal of this research is to understand and describe specific aspects of molecular interaction, it includes studying various aspects such as binding affinity, binding mode, and stability of the ligand-protein complex. Molecular docking is a computational technique used to predict the preferred orientation of one molecule to a second when bound together to form a stable complex. In this study, molecular docking will be employed to stimulate and analyze the interaction between the ligand and the target protein. Identifying the phytocompounds for the treatment of Polycystic ovary syndrome involves exploring the plant-derived compounds with potential therapeutic effects on the symptoms and underlying mechanisms of the condition. Methods: In this study, an in silico study to develop the best phytocompounds to treat polycystic ovary syndrome (PCOS). IMPPAT database was used to retrieve the phytocompounds from Curcuma longa. The molecules selected underwent drug-likeness screening on SwissADME, and final screening was conducted using PyRx software, revealing the binding affinity between the ligands and the 1h59 target protein. The examination of 3D interactions was carried out using BIOVIA. Results: The potential lead molecules are Cinnamyl cinnamate, ar-Turmerone, and alpha-curcumene from Curcuma longa were identified to resist the insulin which helps to treat polycystic ovarian syndrome. Conclusion: All three compounds, namely cinnamyl cinnamate, ar-Turmerone, and alpha-curcumene, comply with Lipinski’s parameters, indicating their suitability for treating PCOS by regulating insulin levels. These lead molecules show prominent results in polycystic ovarian syndrome.

Keywords

References (34)

  1. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine Reviews. 2016;37(5):467-520. doi:10.1210/er.2015-1104
  2. Badawy A, Elnashar. Treatment options for polycystic ovary syndrome. International Journal of Women's Health. 2011:25. doi:10.2147/ijwh.s11304
  3. Galluzzo A, Amato MC, Giordano C. Insulin resistance and polycystic ovary syndrome. Nutrition, Metabolism and Cardiovascular Diseases. 2008;18(7):511-518. doi:10.1016/j.numecd.2008.05.004
  4. Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, et al. Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. International Journal of Reproductive Medicine. 2014;2014:1-17. doi:10.1155/2014/719050
  5. Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, Challenges, and Guiding Treatment. The Journal of Clinical Endocrinology & Metabolism. 2020;106(3):e1071-e1083. doi:10.1210/clinem/dgaa839
  6. Azziz R. Polycystic Ovary Syndrome, Insulin Resistance, and Molecular Defects of Insulin Signaling. The Journal of Clinical Endocrinology & Metabolism. 2002;87(9):4085-4087. doi:10.1210/jc.2002-021131
  7. Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*. Endocrine Reviews. 1997;18(6):774-800. doi:10.1210/edrv.18.6.0318
  8. Papalou O, Livadas S, Karachalios A, Tolia N, Kokkoris P, Tripolitakis K, et al. White blood cells levels and PCOS: direct and indirect relationship with obesity and insulin resistance, but not with hyperandogenemia. Hormones. 2015;14(1):91-100. doi:10.14310/horm.2002.1563
  9. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends in Molecular Medicine. 2006;12(7):324-332. doi:10.1016/j.molmed.2006.05.006
  10. Tosi F, Bonora E, Moghetti P. Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Human Reproduction. 2017;32(12):2515-2521. doi:10.1093/humrep/dex308
  11. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Advances in Clinical and Experimental Medicine. 2017;26(2):359-367. doi:10.17219/acem/59380
  12. Żesławski W, Beisel HG, Kamionka M, Kalus W, Engh RA, Huber R, et al. The interaction of insulin‐like growth factor‐I with the N‐terminal domain of IGFBP‐5. The EMBO Journal. 2001;20(14):3638-3644. doi:10.1093/emboj/20.14.3638
  13. EMBL's European Bioinformatics Institute. (2023). PROCHECK and PROCHECK-NMR. PROCHECK home page. [online] Ebi.ac.uk. Available from: https://www.ebi.ac.uk/thornton-srv/software/PROCHECK/.
  14. Żesławski W, Beisel HG, Kamionka M, Kalus W, Engh RA, Huber R, et al. The interaction of insulin‐like growth factor‐I with the N‐terminal domain of IGFBP‐5. The EMBO Journal. 2001;20(14):3638-3644. doi:10.1093/emboj/20.14.3638
  15. PubChem. NLM. NIH. (2024). PubChem. [online] National Library of Medicine. National Institutes of Health. Available from: https://pubchem.ncbi.nlm.nih.gov/
  16. Areejit Samal. (2022). IMPPAT: Indian Medicinal Plants, Phytochemistry And Therapeutics. [online] IMPPAT. Available from: https://cb.imsc.res.in/imppat/
  17. Swiss Institute of Bioinformatics. (2024). SwissADME. [online] Molecular Modeling Group, Swiss Institute of Bioinformatics. Available from: http://www.swissadme.ch/
  18. Dassault Systèmes (2020). Free Download: BIOVIA Discovery Studio Visualizer. [online] Dassault Systèmes. Available from: https://discover.3ds.com/discovery-studio-visualizer-download
  19. SourceForge. (2024). Welcome to the PyRx Website. Virtual Screening Tool. [online] Available from: https://pyrx.sourceforge.io/
  20. Mastorakos G, Lambrinoudaki I, Creatsas G. Polycystic Ovary Syndrome in Adolescents. Pediatric Drugs. 2006;8(5):311-318. doi:10.2165/00148581-200608050-00004
  21. Laskowski RA, MacArthur MW, Thornton JM. PROCHECK: Validation of protein-structure coordinates. In: International Tables for Crystallography. Chester, England: International Union of Crystallography; 2012. p. 684–7.
  22. Teede HJ, Hutchison SK, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends in Endocrinology & Metabolism. 2007;18(7):273-279. doi:10.1016/j.tem.2007.08.001
  23. Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertility and Sterility. 2003;80(2):255-258. doi:10.1016/s0015-0282(03)00734-9
  24. Al Khalifah RA, Flórez ID, Dennis B, Neupane B, Thabane L, Bassilious E. The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol. Systematic Reviews. 2015;4(1). doi:10.1186/s13643-015-0105-4
  25. Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertility and Sterility. 2012;97(1):18-22. doi:10.1016/j.fertnstert.2011.11.036
  26. Homburg R. The management of infertility associated with polycystic ovary syndrome. Reproductive Biology and Endocrinology. 2003;1(1). doi:10.1186/1477-7827-1-109
  27. Ramezani Tehrani F, Amiri M. Polycystic Ovary Syndrome in Adolescents: Challenges in Diagnosis and Treatment. International Journal of Endocrinology and Metabolism. 2019;17(3). doi:10.5812/ijem.91554
  28. Carmina E, Lobo RA. Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women. The Journal of Clinical Endocrinology & Metabolism. 1999;84(6):1897-1899. doi:10.1210/jcem.84.6.5803
  29. Balkrishna A, Rana M, Mishra S, Srivastava D, Bhardwaj R, Singh S, et al. Incredible Combination of Lifestyle Modification and Herbal Remedies for Polycystic Ovarian Syndrome Management. Evidence-Based Complementary and Alternative Medicine. 2023;2023(1). doi:10.1155/2023/3705508
  30. Jin P, Xie Y. Treatment strategies for women with polycystic ovary syndrome. Gynecological Endocrinology. 2017;34(4):272-277. doi:10.1080/09513590.2017.1395841
  31. Traub ML. Assessing and treating insulin resistance in women with polycystic ovarian syndrome. World Journal of Diabetes. 2011;2(3):33. doi:10.4239/wjd.v2.i3.33
  32. Ebrahimi‐Mamaghani M, Saghafi‐Asl M, Pirouzpanah S, Asghari‐Jafarabadi M. Effects of raw red onion consumption on metabolic features in overweight or obese women with polycystic ovary syndrome: A randomized controlled clinical trial. Journal of Obstetrics and Gynaecology Research. 2014;40(4):1067-1076. doi:10.1111/jog.12311
  33. Naeimi SA, Hajimehdipoor H, Saber S. Comparing the effect of Nigella sativa oil soft gel and placebo on oligomenorrhea, amenorrhea and laboratory characteristics in patients with polycystic ovarian syndrome, a randomized clinical trial. Res J Pharmacogn. 2020;7:49–59.
  34. Chavez GN, Jaworsky K, Basu A. The Effects of Plant-Derived Phytochemical Compounds and Phytochemical-Rich Diets on Females with Polycystic Ovarian Syndrome: A Scoping Review of Clinical Trials. International Journal of Environmental Research and Public Health. 2023;20(15):6534. doi:10.3390/ijerph20156534